These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 1551646)

  • 1. Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease.
    Colombo C; Castellani MR; Balistreri WF; Seregni E; Assaisso ML; Giunta A
    Hepatology; 1992 Apr; 15(4):677-84. PubMed ID: 1551646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delayed intestinal visualization at hepatobiliary scintigraphy is associated with response to long-term treatment with ursodeoxycholic acid in patients with cystic fibrosis-associated liver disease.
    Colombo C; Crosignani A; Battezzati PM; Castellani MR; Comi S; Melzi ML; Giunta A
    J Hepatol; 1999 Oct; 31(4):672-7. PubMed ID: 10551391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of hepatobiliary scintigraphy in cystic fibrosis.
    O'Connor PJ; Southern KW; Bowler IM; Irving HC; Robinson PJ; Littlewood JM
    Hepatology; 1996 Feb; 23(2):281-7. PubMed ID: 8591853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: a dose-response study.
    Colombo C; Crosignani A; Assaisso M; Battezzati PM; Podda M; Giunta A; Zimmer-Nechemias L; Setchell KD
    Hepatology; 1992 Oct; 16(4):924-30. PubMed ID: 1398498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive study of the biliary bile acid composition of patients with cystic fibrosis and associated liver disease before and after UDCA administration.
    Nakagawa M; Colombo C; Setchell KD
    Hepatology; 1990 Aug; 12(2):322-34. PubMed ID: 2391071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term prospective study of the effect of ursodeoxycholic acid on cystic fibrosis-related liver disease.
    Nousia-Arvanitakis S; Fotoulaki M; Economou H; Xefteri M; Galli-Tsinopoulou A
    J Clin Gastroenterol; 2001 Apr; 32(4):324-8. PubMed ID: 11276276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatobiliary scintigraphy in children with cystic fibrosis and liver disease.
    Dogan AS; Conway JJ; Lloyd-Still JD
    J Nucl Med; 1994 Mar; 35(3):432-5. PubMed ID: 8113890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis.
    Colombo C; Setchell KD; Podda M; Crosignani A; Roda A; Curcio L; Ronchi M; Giunta A
    J Pediatr; 1990 Sep; 117(3):482-9. PubMed ID: 2391610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver disease and common-bile-duct stenosis in cystic fibrosis.
    Gaskin KJ; Waters DL; Howman-Giles R; de Silva M; Earl JW; Martin HC; Kan AE; Brown JM; Dorney SF
    N Engl J Med; 1988 Feb; 318(6):340-6. PubMed ID: 3340104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum bile acids and ursodeoxycholic acid treatment in cystic fibrosis-related liver disease.
    O'Brien SM; Campbell GR; Burke AF; Maguire OC; Rowlands BJ; FitzGerald MX; Hegarty JE
    Eur J Gastroenterol Hepatol; 1996 May; 8(5):477-83. PubMed ID: 8804877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatobiliary scintigraphy as a liver function test.
    Heyman S
    J Nucl Med; 1994 Mar; 35(3):436-7. PubMed ID: 8113891
    [No Abstract]   [Full Text] [Related]  

  • 12. Liver disease and bile duct abnormalities in adults with cystic fibrosis.
    Nagel RA; Westaby D; Javaid A; Kavani J; Meire HB; Lombard MG; Wise A; Williams R; Hodson ME
    Lancet; 1989 Dec; 2(8677):1422-5. PubMed ID: 2574362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease.
    Lindblad A; Glaumann H; Strandvik B
    Hepatology; 1998 Jan; 27(1):166-74. PubMed ID: 9425933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ursodeoxycholic acid therapy in hepatobiliary disease.
    Kowdley KV
    Am J Med; 2000 Apr; 108(6):481-6. PubMed ID: 10781781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ursodeoxycholic acid treatment in patients with cystic fibrosis at risk for liver disease.
    Siano M; De Gregorio F; Boggia B; Sepe A; Ferri P; Buonpensiero P; Di Pasqua A; Raia V
    Dig Liver Dis; 2010 Jun; 42(6):428-31. PubMed ID: 20034860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver disease in cystic fibrosis.
    Colombo C; Apostolo MG; Assaisso M; Roman B; Bottani P
    Neth J Med; 1992 Oct; 41(3-4):119-22. PubMed ID: 1470280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrahepatic bile duct dilatation and cholestasis in autosomal recessive polycystic kidney disease. Demonstration with hepatobiliary scintigraphy.
    Waters K; Howman-Giles R; Rossleigh M; Lam A; Uren R; Knight J
    Clin Nucl Med; 1995 Oct; 20(10):892-5. PubMed ID: 8616994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Ursodeoxycholic Acid Therapy Does Not Alter Lithocholic Acid Levels in Patients with Cystic Fibrosis with Associated Liver Disease.
    Colombo C; Crosignani A; Alicandro G; Zhang W; Biffi A; Motta V; Corti F; Setchell KDR
    J Pediatr; 2016 Oct; 177():59-65.e1. PubMed ID: 27297203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of ursodeoxycholic acid treatment on nutrition and liver function in patients with cystic fibrosis and longstanding cholestasis.
    Cotting J; Lentze MJ; Reichen J
    Gut; 1990 Aug; 31(8):918-21. PubMed ID: 2387518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endogenous ursodeoxycholic acid and cholic acid in liver disease due to cystic fibrosis.
    Smith JL; Lewindon PJ; Hoskins AC; Pereira TN; Setchell KD; O'Connell NC; Shepherd RW; Ramm GA
    Hepatology; 2004 Jun; 39(6):1673-82. PubMed ID: 15185309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.